Tirzepatide

5mg · Lyophilized Powder

VIAL SIZE

$70.00 CAD

Tirzepatide is a dual GIP and GLP-1 receptor agonist — the first-in-class peptide to simultaneously target both incretin pathways for metabolic modulation. In Phase 3 SURMOUNT trials, weekly subcutaneous administration produced body weight reductions of up to 22.5% over 72 weeks. The triple-action mechanism includes appetite suppression, enhanced insulin secretion, and increased energy expenditure, with a C20 fatty diacid conjugate enabling once-weekly dosing at a half-life of approximately 5 days. Research continues to explore its effects on cardiovascular outcomes and non-alcoholic fatty liver disease.

Research Applications

•Dual GIP/GLP-1 receptor agonism for superior metabolic recomposition

•Body weight and adiposity reduction in obesity research models

•Insulin sensitivity and postprandial glucose regulation

•Appetite and energy intake modulation via dual incretin pathways

•Cardiovascular and hepatic metabolic marker research

•Lean mass preservation during caloric-deficit research protocols

VIEW CERTIFICATE OF ANALYSIS (COA) →VIEW DOSING PROTOCOL →

Compare:Tirzepatide vs Retatrutide →Semaglutide vs Tirzepatide vs Retatrutide →Mazdutide vs Tirzepatide →

1

SHARE

All products sold by JA Performance Peptides are intended strictly for laboratory research purposes and are not approved for human consumption, veterinary use, or therapeutic application. Not for human use.